KRAS and colonic neoplasm: Several studies have shown that the majority of MEK inhibitor-insensitive colon cancer cell lines harbour activating mutations in the PI3K pathway, whereas KRAS mutant cancer cells with an intact wild-type PI3K pathway are sensitive to MEK inhibitors.9